Iptacopan Improves Hematologic, Clinical Outcomes in Persistent Anemia

TUESDAY, March 19, 2024-- The first-in-class oral factor B inhibitor iptacopan improves hematologic and clinical outcomes in anti-C5-treated patients with persistent anemia and in those who have not received complement inhibitors, according to a...